For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Empagliflozin - Heart failure
PAD Profile : Empagliflozin - Heart failure
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Eplerenone
- Ivabradine
- Sacubitril/valsartan
- Digoxin
- Spironolactone
- Dapagliflozin
- Metolazone
- Ramipril
- Captopril
- Enalapril maleate
- Lisinopril
- Perindopril erbumine
- Bisoprolol fumarate
- Carvedilol
- Nebivolol
- Candesartan cilexetil
- Losartan potassium
- Valsartan
- Prazosin hydrochloride
- Hydralazine hydrochloride
- Acetazolamide
- Enoximone
- Milrinone lactate
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin:
- as an option for treating adult chronic heart failure with reduced ejection fraction in addition to standard care (NICE TA773)
- as an option for treating adult chronic heart failure with preserved or mildly reduced ejection fraction in addition to standard care (NICE TA929)
Treatment should be initiated or recommended by a heart failure specialist in patients with a formal diagnosis of heart failure as per NICE guideline on Chronic Heart Failure in adults
Heart Failure specialist defined as:
• Cardiology consultant, specialist, or registrar
• Heart failure specialist nurse
• GP with a specialist interest in heart failure or GP cardiologist
• General physician with heart failure expertise
• Renal physician
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a BLUE information sheet for empagliflozin and dapagliflozin for Adult Heart Failure with reduced ejection fraction (HFrEF) and a place in therapy document for these treatments in patients with Heart Failure.